Antitumor activity and immune response induction of a dual agonist of Toll-like receptors 7 and 8.

abstract：:Passive immunotherapy with monoclonal antibodies represents a cornerstone of human anticancer therapies, but has not been established in veterinary medicine yet. As the tumor-associated antigen EGFR (ErbB-1) is highly conserved between humans and dogs, and considering the effectiveness of the anti-EGFR antibody cetuxi...

journal_title：Molecular cancer therapeutics

authors： Singer J,Fazekas J,Wang W,Weichselbaumer M,Matz M,Mader A,Steinfellner W,Meitz S,Mechtcheriakova D,Sobanov Y,Willmann M,Stockner T,Spillner E,Kunert R,Jensen-Jarolim E

更新日期：2014-07-01 00:00:00

abstract：:Stromal myofibroblasts play an important role in tumor progression. The transition of fibroblasts to myofibroblasts is characterized by expression of smooth muscle genes and profuse synthesis of extracellular matrix proteins. We evaluated the efficacy of targeting fibroblast-to-myofibroblast transition with halofugino...

journal_title：Molecular cancer therapeutics

authors： Sheffer Y,Leon O,Pinthus JH,Nagler A,Mor Y,Genin O,Iluz M,Kawada N,Yoshizato K,Pines M

更新日期：2007-02-01 00:00:00

abstract：:Germ cell tumors (GCT) are malignant tumors that arise from pluripotent embryonic germ cells and occur in children and young adults. GCTs are treated with cisplatin-based regimens which, while overall effective, fail to cure all patients and cause significant adverse late effects. The seminoma and nonseminoma forms of...

journal_title：Molecular cancer therapeutics

authors： Chen KS,Fustino NJ,Shukla AA,Stroup EK,Budhipramono A,Ateek C,Stuart SH,Yamaguchi K,Kapur P,Frazier AL,Lum L,Looijenga LHJ,Laetsch TW,Rakheja D,Amatruda JF

更新日期：2018-05-01 00:00:00

abstract：:STAT3 has been recognized for its key role in the progression of cancer, where it is frequently upregulated or constitutively hyperactivated, contributing to tumor cell proliferation, survival, and migration, as well as angiogenesis and suppression of antitumor immunity. Given the ubiquity of dysregulated STAT3 activi...

journal_title：Molecular cancer therapeutics

authors： Shiah JV,Grandis JR,Johnson DE

更新日期：2020-11-17 00:00:00

abstract：:Hsp70 is a stress-inducible molecular chaperone that is required for cancer development at several steps. Targeting the active site of Hsp70 has proven relatively challenging, driving interest in alternative approaches. Hsp70 collaborates with the Bcl2-associated athanogene 3 (Bag3) to promote cell survival through mu...

journal_title：Molecular cancer therapeutics

authors： Li X,Colvin T,Rauch JN,Acosta-Alvear D,Kampmann M,Dunyak B,Hann B,Aftab BT,Murnane M,Cho M,Walter P,Weissman JS,Sherman MY,Gestwicki JE

更新日期：2015-03-01 00:00:00

abstract：:Ewing's sarcoma is a pediatric cancer of the bone that is characterized by the expression of the chimeric transcription factor EWS-FLI1 that confers a highly malignant phenotype and results from the chromosomal translocation t(11;22)(q24;q12). Poor overall survival and pronounced long-term side effects associated with...

journal_title：Molecular cancer therapeutics

authors： Winter GE,Rix U,Lissat A,Stukalov A,Müllner MK,Bennett KL,Colinge J,Nijman SM,Kubicek S,Kovar H,Kontny U,Superti-Furga G

更新日期：2011-10-01 00:00:00

abstract：:Integrin-linked kinase (ILK) was assesed as a therapeutic target in glioblastoma xenograft models through multiple endpoints including treatment related changes in the tumor microenvironment. Glioblastoma cell lines were tested in vitro for sensitivity toward the small-molecule inhibitors QLT0254 and QLT0267. Cell via...

journal_title：Molecular cancer therapeutics

authors： Edwards LA,Woo J,Huxham LA,Verreault M,Dragowska WH,Chiu G,Rajput A,Kyle AH,Kalra J,Yapp D,Yan H,Minchinton AI,Huntsman D,Daynard T,Waterhouse DN,Thiessen B,Dedhar S,Bally MB

更新日期：2008-01-01 00:00:00

abstract：:Antibody-drug conjugates (ADC) represent a promising therapeutic modality for managing cancer. Here, we report a novel humanized ADC that targets the tetraspanin-like protein TM4SF1. TM4SF1 is highly expressed on the plasma membranes of many human cancer cells and also on the endothelial cells lining tumor blood vesse...

journal_title：Molecular cancer therapeutics

authors： Visintin A,Knowlton K,Tyminski E,Lin CI,Zheng X,Marquette K,Jain S,Tchistiakova L,Li D,O'Donnell CJ,Maderna A,Cao X,Dunn R,Snyder WB,Abraham AK,Leal M,Shetty S,Barry A,Zawel L,Coyle AJ,Dvorak HF,Jaminet SC

更新日期：2015-08-01 00:00:00

abstract：:The development of new drugs against cancer requires established cell lines. They are needed for in vitro studies to identify candidate drugs and in xenograft models to measure drug efficacy in vivo. Specific criteria need to be fulfilled by cell lines used in the evaluation of potential novel therapeutic agents. It i...

journal_title：Molecular cancer therapeutics

authors： Kees UR,Ford J,Watson M,Murch A,Ringńer M,Walker RL,Meltzer P

更新日期：2003-07-01 00:00:00

abstract：:Cell cycle regulators, such as the CDC25 phosphatases, are potential targets for the development of new anticancer drugs. Here we report the identification and the characterization of BN82685, a quinone-based CDC25 inhibitor that is active in vitro and in vivo. BN82685 inhibits recombinant CDC25A, B, and C phosphatase...

journal_title：Molecular cancer therapeutics

authors： Brezak MC,Quaranta M,Contour-Galcera MO,Lavergne O,Mondesert O,Auvray P,Kasprzyk PG,Prevost GP,Ducommun B

更新日期：2005-09-01 00:00:00

abstract：:To investigate the mechanism by which 5-aminoimidazole-4-carboxamide-1-β-riboside (AICAr) induces apoptosis in multiple myeloma cells, we conducted an unbiased metabolomics screen. AICAr had selective effects on nucleotide metabolism, resulting in an increase in purine metabolites and a decrease in pyrimidine metaboli...

journal_title：Molecular cancer therapeutics

authors： Bardeleben C,Sharma S,Reeve JR,Bassilian S,Frost P,Hoang B,Shi Y,Lichtenstein A

更新日期：2013-07-01 00:00:00

abstract：:The Notch signaling pathway has been implicated in cell fate determination and differentiation in many tissues. Accumulating evidence points toward a pivotal role in blood vessel formation, and the importance of the Delta-like ligand (Dll) 4-Notch1 ligand-receptor interaction has been shown in both physiological and t...

journal_title：Molecular cancer therapeutics

authors： Jenkins DW,Ross S,Veldman-Jones M,Foltz IN,Clavette BC,Manchulenko K,Eberlein C,Kendrew J,Petteruti P,Cho S,Damschroder M,Peng L,Baker D,Smith NR,Weir HM,Blakey DC,Bedian V,Barry ST

更新日期：2012-08-01 00:00:00

abstract：:Multiple roles within mitosis have been assigned to Polo-like kinase 1 (Plk1), making it an attractive candidate for mitotic targeting of cancer cells. We have employed chimeric antisense oligonucleotides to investigate the molecular alterations after targeted interference with Plk1 in RKO human colon adenocarcinoma a...

journal_title：Molecular cancer therapeutics

authors： Schmidt M,Hofmann HP,Sanders K,Sczakiel G,Beckers TL,Gekeler V

更新日期：2006-04-01 00:00:00

abstract：:Ovarian cancer is the leading cause of death from gynecologic cancer. Often, the disease has spread beyond the ovary to involve the peritoneal cavity and causes ascites. Whereas mammalian target of rapamycin (mTOR) functions to regulate protein translation, cell cycle progression, and metastasis, vascular endothelial ...

journal_title：Molecular cancer therapeutics

authors： Huynh H,Teo CC,Soo KC

更新日期：2007-11-01 00:00:00

abstract：:Using a luciferase reporter-based high-throughput chemical library screen and topological data analysis, we identified N-acridine-9-yl-N',N'-dimethylpropane-1,3-diamine (DAPA) as an inhibitor of the inositol requiring kinase 1α (IRE1α)-X-box binding protein-1 (XBP1) pathway of the unfolded protein response. We designe...

journal_title：Molecular cancer therapeutics

authors： Jiang D,Tam AB,Alagappan M,Hay MP,Gupta A,Kozak MM,Solow-Cordero DE,Lum PY,Denko NC,Giaccia AJ,Le QT,Niwa M,Koong AC

更新日期：2016-09-01 00:00:00

abstract：:The camptothecin derivatives topoisomerase I (TOP1) inhibitors, irinotecan and topotecan, are FDA approved for the treatment of colorectal, ovarian, lung and breast cancers. Because of the chemical instability of camptothecins, short plasma half-life, drug efflux by the multidrug-resistance ABC transporters, and the s...

journal_title：Molecular cancer therapeutics

authors： Marzi L,Sun Y,Huang SN,James A,Difilippantonio S,Pommier Y

更新日期：2020-08-01 00:00:00

abstract：:Human epidermal growth factor receptor-2 (HER2) and epidermal growth factor receptor (EGFR) heterodimerize to activate mitogenic signaling pathways. We have shown previously, using MCF7 subcloned cell lines with graded levels of HER2 expression, that responsiveness to trastuzumab and AG1478 (an anti-EGFR agent), varie...

journal_title：Molecular cancer therapeutics

authors： Emlet DR,Brown KA,Kociban DL,Pollice AA,Smith CA,Ong BB,Shackney SE

更新日期：2007-10-01 00:00:00

abstract：:Radiotherapy, a frequent mode of cancer treatment, is often restricted by dose-related toxicity and development of therapeutic resistance. To develop a novel and selective radiosensitizer, we studied the radiosensitizing effects and associated mechanisms of silibinin in prostate cancer. The radiosensitizing effect of ...

journal_title：Molecular cancer therapeutics

authors： Nambiar DK,Rajamani P,Deep G,Jain AK,Agarwal R,Singh RP

更新日期：2015-12-01 00:00:00

abstract：:Endocrine therapy has been highly effective for the treatment of estrogen receptor-positive breast cancer, but endocrine resistance develops in a significant proportion of patients. In an effort to develop novel therapeutic strategies for the treatment of endocrine-resistant breast cancer, we have evaluated a potent a...

journal_title：Molecular cancer therapeutics

authors： Lu J,McEachern D,Li S,Ellis MJ,Wang S

更新日期：2016-12-01 00:00:00

abstract：:Hormone refractory metastatic prostate cancer is a deadly disease that currently lacks curative treatments. Conditionally replicating adenoviruses (CRAds) are promising new agents against cancer due to their innate capability to cause oncolysis of tumor cells. Their antitumor effect is determined in part by their capa...

journal_title：Molecular cancer therapeutics

authors： Rajecki M,Kanerva A,Stenman UH,Tenhunen M,Kangasniemi L,Särkioja M,Ala-Opas MY,Alfthan H,Sankila A,Rintala E,Desmond RA,Hakkarainen T,Hemminki A

更新日期：2007-02-01 00:00:00

abstract：:Malignant ascitis (MA) is a highly intractable and immunotherapy-resistant state of advanced gastrointestinal and ovarian cancers. Using a murine model of MA with CT26 colon cancer cells, we here determined that the imbalance between the VEGF-A/vascular permeability factor and its decoy receptor, soluble fms-like tryr...

journal_title：Molecular cancer therapeutics

authors： Sugiyama M,Kakeji Y,Tsujitani S,Harada Y,Onimaru M,Yoshida K,Tanaka S,Emi Y,Morita M,Morodomi Y,Hasegawa M,Maehara Y,Yonemitsu Y

更新日期：2011-03-01 00:00:00

abstract：:In recent years, HER3 has increasingly been implicated in the progression of a variety of tumor types and in acquired resistance to EGFR and HER2 therapies. Whereas EGFR and HER2 primarily signal through the MAPK pathway, HER3, as a heterodimer with EGFR or HER2, potently activates the PI3K pathway. Despite its critic...

journal_title：Molecular cancer therapeutics

authors： Thakkar D,Sancenon V,Taguiam MM,Guan S,Wu Z,Ng E,Paszkiewicz KH,Ingram PJ,Boyd-Kirkup JD

更新日期：2020-02-01 00:00:00

abstract：:Increasing literature suggests that cell adhesion molecule alpha4beta1 integrin plays a pivotal role in autoimmune diseases and cancer development. Noninvasive visualization of alpha4beta1 integrin in vivo will facilitate the understanding of its involvement in disease progression and development of targeted therapies...

journal_title：Molecular cancer therapeutics

authors： Peng L,Liu R,Andrei M,Xiao W,Lam KS

更新日期：2008-02-01 00:00:00

abstract：:PHA-739358 is a small-molecule 3-aminopyrazole derivative with strong activity against Aurora kinases and cross-reactivities with some receptor tyrosine kinases relevant for cancer. PHA-739358 inhibits all Aurora kinase family members and shows a dominant Aurora B kinase inhibition-related cellular phenotype and mecha...

journal_title：Molecular cancer therapeutics

authors： Carpinelli P,Ceruti R,Giorgini ML,Cappella P,Gianellini L,Croci V,Degrassi A,Texido G,Rocchetti M,Vianello P,Rusconi L,Storici P,Zugnoni P,Arrigoni C,Soncini C,Alli C,Patton V,Marsiglio A,Ballinari D,Pesenti E,Fan

更新日期：2007-12-01 00:00:00

abstract：:Mps1 is a dual specificity protein kinase that is essential for the bipolar attachment of chromosomes to the mitotic spindle and for maintaining the spindle assembly checkpoint until all chromosomes are properly attached. Mps1 is expressed at high levels during mitosis and is abundantly expressed in cancer cells. Disr...

journal_title：Molecular cancer therapeutics

authors： Tardif KD,Rogers A,Cassiano J,Roth BL,Cimbora DM,McKinnon R,Peterson A,Douce TB,Robinson R,Dorweiler I,Davis T,Hess MA,Ostanin K,Papac DI,Baichwal V,McAlexander I,Willardsen JA,Saunders M,Christophe H,Kumar DV,Wet

更新日期：2011-12-01 00:00:00

abstract：:Glycosylation is a complex multienzyme-related process that is frequently deregulated in cancer. Aberrant glycosylation can lead to the generation of novel tumor surface-specific glycotopes that can be targeted by antibodies. Murine DS6 mAb (muDS6) was generated from serous ovary adenocarcinoma immunization. It recogn...

journal_title：Molecular cancer therapeutics

authors： Nicolazzi C,Caron A,Tellier A,Trombe M,Pinkas J,Payne G,Carrez C,Guérif S,Maguin M,Baffa R,Fassan M,Adam J,Mangatal-Wade L,Blanc V

更新日期：2020-08-01 00:00:00

abstract：:Clear cell renal cell carcinoma (CC-RCC) is a devastating disease with limited therapeutic options available for advanced stages. The objective of this study was to investigate HMG-CoA reductase inhibitors, also known as statins, as potential therapeutics for CC-RCC. Importantly, treatment with statins was found to be...

journal_title：Molecular cancer therapeutics

authors： Thompson JM,Alvarez A,Singha MK,Pavesic MW,Nguyen QH,Nelson LJ,Fruman DA,Razorenova OV

更新日期：2018-08-01 00:00:00

abstract：:G-protein-coupled receptors (GPCR) activate the epidermal growth factor receptor (EGFR) and mediate EGFR-independent signaling pathways to promote the growth of a variety of cancers, including head and neck squamous cell carcinoma (HNSCC). Identification of the common signaling mechanisms involved in GPCR-induced EGFR...

journal_title：Molecular cancer therapeutics

authors： Bhola NE,Freilino ML,Joyce SC,Sen M,Thomas SM,Sahu A,Cassell A,Chen CS,Grandis JR

更新日期：2012-06-01 00:00:00

abstract：:DMOT4039A, a humanized anti-mesothelin mAb conjugated to the antimitotic agent monomethyl auristatin E (MMAE), was given to patients with pancreatic and ovarian cancer every 3 weeks (0.2-2.8 mg/kg; q3w) or weekly (0.8-1.2 mg/kg). A 3+3 design was used for dose escalation followed by expansion at the recommended phase ...

journal_title：Molecular cancer therapeutics

authors： Weekes CD,Lamberts LE,Borad MJ,Voortman J,McWilliams RR,Diamond JR,de Vries EG,Verheul HM,Lieu CH,Kim GP,Wang Y,Scales SJ,Samineni D,Brunstein F,Choi Y,Maslyar DJ,Colon-Otero G

更新日期：2016-03-01 00:00:00

abstract：:Acquired resistance to cancer drugs is common, also for modern targeted drugs like the Bruton tyrosine kinase (BTK) inhibitor ibrutinib, a new drug approved for the treatment of the highly aggressive and relapsing mantle cell lymphoma (MCL). The tumor microenvironment often impacts negatively on drug response. Here, w...

journal_title：Molecular cancer therapeutics

authors： Guan J,Huang D,Yakimchuk K,Okret S

更新日期：2018-05-01 00:00:00